S&P 500   4,294.29 (+0.28%)
DOW   33,697.10 (-0.19%)
QQQ   357.09 (+0.69%)
AAPL   184.52 (+1.97%)
MSFT   337.87 (+0.74%)
META   274.42 (+0.66%)
GOOGL   126.95 (+1.83%)
AMZN   125.15 (+0.72%)
TSLA   217.97 (+1.87%)
NVDA   390.96 (-0.59%)
NIO   7.77 (+2.78%)
BABA   83.94 (-0.39%)
AMD   119.06 (+1.02%)
T   15.35 (+0.92%)
F   12.64 (+2.02%)
MU   68.29 (-1.27%)
CGC   0.79 (-4.54%)
GE   104.54 (-1.19%)
DIS   90.57 (-0.22%)
AMC   4.61 (+1.32%)
PFE   38.83 (+1.23%)
PYPL   64.88 (+1.44%)
NFLX   410.49 (+2.50%)
S&P 500   4,294.29 (+0.28%)
DOW   33,697.10 (-0.19%)
QQQ   357.09 (+0.69%)
AAPL   184.52 (+1.97%)
MSFT   337.87 (+0.74%)
META   274.42 (+0.66%)
GOOGL   126.95 (+1.83%)
AMZN   125.15 (+0.72%)
TSLA   217.97 (+1.87%)
NVDA   390.96 (-0.59%)
NIO   7.77 (+2.78%)
BABA   83.94 (-0.39%)
AMD   119.06 (+1.02%)
T   15.35 (+0.92%)
F   12.64 (+2.02%)
MU   68.29 (-1.27%)
CGC   0.79 (-4.54%)
GE   104.54 (-1.19%)
DIS   90.57 (-0.22%)
AMC   4.61 (+1.32%)
PFE   38.83 (+1.23%)
PYPL   64.88 (+1.44%)
NFLX   410.49 (+2.50%)
S&P 500   4,294.29 (+0.28%)
DOW   33,697.10 (-0.19%)
QQQ   357.09 (+0.69%)
AAPL   184.52 (+1.97%)
MSFT   337.87 (+0.74%)
META   274.42 (+0.66%)
GOOGL   126.95 (+1.83%)
AMZN   125.15 (+0.72%)
TSLA   217.97 (+1.87%)
NVDA   390.96 (-0.59%)
NIO   7.77 (+2.78%)
BABA   83.94 (-0.39%)
AMD   119.06 (+1.02%)
T   15.35 (+0.92%)
F   12.64 (+2.02%)
MU   68.29 (-1.27%)
CGC   0.79 (-4.54%)
GE   104.54 (-1.19%)
DIS   90.57 (-0.22%)
AMC   4.61 (+1.32%)
PFE   38.83 (+1.23%)
PYPL   64.88 (+1.44%)
NFLX   410.49 (+2.50%)
S&P 500   4,294.29 (+0.28%)
DOW   33,697.10 (-0.19%)
QQQ   357.09 (+0.69%)
AAPL   184.52 (+1.97%)
MSFT   337.87 (+0.74%)
META   274.42 (+0.66%)
GOOGL   126.95 (+1.83%)
AMZN   125.15 (+0.72%)
TSLA   217.97 (+1.87%)
NVDA   390.96 (-0.59%)
NIO   7.77 (+2.78%)
BABA   83.94 (-0.39%)
AMD   119.06 (+1.02%)
T   15.35 (+0.92%)
F   12.64 (+2.02%)
MU   68.29 (-1.27%)
CGC   0.79 (-4.54%)
GE   104.54 (-1.19%)
DIS   90.57 (-0.22%)
AMC   4.61 (+1.32%)
PFE   38.83 (+1.23%)
PYPL   64.88 (+1.44%)
NFLX   410.49 (+2.50%)
NASDAQ:DNAY

Telesis Bio (DNAY) Stock Forecast, Price & News

$1.30
+0.10 (+8.33%)
(As of 01/3/2023)
Compare
Today's Range
$1.20
$1.31
50-Day Range
$1.52
$3.02
52-Week Range
$1.08
$11.02
Volume
19,900 shs
Average Volume
54,063 shs
Market Capitalization
$38.38 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

Telesis Bio MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
284.6% Upside
$5.00 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.85) to ($1.32) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.01 out of 5 stars

Medical Sector

514th out of 980 stocks

Analytical Instruments Industry

16th out of 27 stocks


DNAY stock logo

About Telesis Bio (NASDAQ:DNAY) Stock

Codex DNA, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Cloud-based scripts; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; Biofoundry Services, which enable a customer to order and receive the BioXp system endpoint-ready products, such as genes, clones, cell-free amplified DNA, and variant libraries; and short oligo ligation assembly enzymatic DNA synthesis. It also serves government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as SGI-DNA, Inc. and changed its name to Codex DNA, Inc. in March 2020. Codex DNA, Inc. was incorporated in 2011 and is headquartered in San Diego, California.

Receive DNAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Telesis Bio and its competitors with MarketBeat's FREE daily newsletter.

DNAY Stock News Headlines

Blue Bird, First Solar rise; Harrow Health, Telesis Bio fall
Stocks that traded heavily or had substantial price changes Friday: Blue Bird, First Solar rise; Harrow Health, Telesis Bio fall
Telesis Bio Inc (TBIO)
AI is Unstoppable. Now Is The Time!
AI, or Artificial Intelligence, is all the rage right now. AI technologies are empowering users in every industry to increase sales, efficiency, and productivity. It's truly a case of adapt or fail.
Telesis Bio: Q4 Earnings Snapshot
AI is Unstoppable. Now Is The Time!
AI, or Artificial Intelligence, is all the rage right now. AI technologies are empowering users in every industry to increase sales, efficiency, and productivity. It's truly a case of adapt or fail.
Telesis Bio, Inc. (DNAY)
Telesis Bio, Inc. (DNAY) Q3 2022 Earnings Call Transcript
DNAY Codex DNA, Inc.
See More Headlines

DNAY Price History

DNAY Company Calendar

Last Earnings
11/08/2021
Today
6/05/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DNAY
Fax
N/A
Employees
212
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.00
High Stock Price Forecast
$5.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+284.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-38,960,000.00
Net Margins
-251.04%
Pretax Margin
-250.94%

Debt

Sales & Book Value

Annual Sales
$21.04 million
Book Value
$3.10 per share

Miscellaneous

Free Float
20,606,000
Market Cap
$38.38 million
Optionable
Not Optionable
Beta
1.36

Key Executives

  • Dr. Todd R. Nelson MBA (Age 55)
    Ph.D., Pres, CEO & Director
    Comp: $876.78k
  • Mr. Daniel G. Gibson Ph.D. (Age 45)
    Chief Technology Officer
    Comp: $436.54k
  • Mr. Eric Esser (Age 52)
    Chief Operating Officer
  • Richard Lepke
    Director of Investor Relations
  • Mr. Robert H. Cutler (Age 54)
    Chief Legal Officer
  • Ms. Laura B. Puga M.B.A. (Age 42)
    VP of People & Culture
  • Mr. Decky Goodrich M.B.A.
    Sr. VP of Commercial Operations
  • Mr. Brent M. Hunter
    Exec. Officer
  • Mr. Laurence Warden
    Sr. VP of Engineering & Instrumentation













DNAY Stock - Frequently Asked Questions

Should I buy or sell Telesis Bio stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Telesis Bio in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" DNAY shares.
View DNAY analyst ratings
or view top-rated stocks.

What is Telesis Bio's stock price forecast for 2023?

1 brokers have issued 1-year target prices for Telesis Bio's shares. Their DNAY share price forecasts range from $5.00 to $5.00. On average, they anticipate the company's stock price to reach $5.00 in the next year. This suggests a possible upside of 284.6% from the stock's current price.
View analysts price targets for DNAY
or view top-rated stocks among Wall Street analysts.

How have DNAY shares performed in 2023?

Telesis Bio's stock was trading at $1.20 on January 1st, 2023. Since then, DNAY stock has increased by 8.3% and is now trading at $1.30.
View the best growth stocks for 2023 here
.

How were Telesis Bio's earnings last quarter?

Telesis Bio, Inc. (NASDAQ:DNAY) announced its earnings results on Monday, November, 8th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.28) by $0.06. The company earned $2.79 million during the quarter, compared to the consensus estimate of $2.93 million. Telesis Bio had a negative net margin of 251.04% and a negative trailing twelve-month return on equity of 73.65%.

When did Telesis Bio IPO?

(DNAY) raised $100 million in an initial public offering (IPO) on Friday, June 18th 2021. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Jefferies, Cowen and KeyBanc Capital Markets served as the underwriters for the IPO.

What is Telesis Bio's stock symbol?

Telesis Bio trades on the NASDAQ under the ticker symbol "DNAY."

Who are Telesis Bio's major shareholders?

Telesis Bio's stock is owned by a number of retail and institutional investors. Top institutional investors include Penn Capital Management Company LLC (1.84%), Penbrook Management LLC (1.16%), Renaissance Technologies LLC (0.32%), Vontobel Holding Ltd. (0.17%), Susquehanna International Group LLP (0.00%) and Two Sigma Investments LP (0.08%).

How do I buy shares of Telesis Bio?

Shares of DNAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Telesis Bio's stock price today?

One share of DNAY stock can currently be purchased for approximately $1.30.

How much money does Telesis Bio make?

Telesis Bio (NASDAQ:DNAY) has a market capitalization of $38.38 million and generates $21.04 million in revenue each year. The company earns $-38,960,000.00 in net income (profit) each year or ($1.80) on an earnings per share basis.

How many employees does Telesis Bio have?

The company employs 212 workers across the globe.

How can I contact Telesis Bio?

The official website for the company is codexdna.com. The company can be reached via phone at 858-228-4115 or via email at ir@codexdna.com.

This page (NASDAQ:DNAY) was last updated on 6/5/2023 by MarketBeat.com Staff

My Account -